関連する実験動画

Updated: Sep 10, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

シノブファギンは,SEC62/TRPM4媒介のNECSOを標的として,多発性骨髄腫株におけるボルテゾミブ耐性を克服する

Zhao Yin¹, Guangchao Li², Qi Zhong¹

¹The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong Province 510317, China.

Phytomedicine : international journal of phytotherapy and phytopharmacology

|August 21, 2025

まとめ

シノブファギンは,TRPM4を安定させ,NECSO細胞死を誘導することによって,多発性骨髄腫におけるボルテゾミブ耐性を克服します. この研究は,SEC62-TRPM4軸を,耐性がんの主要な治療標的として特定しています.

科学分野:

腫瘍学
細胞生物学
薬理学について

背景:

ナトリウム過負荷による死滅 (NECSO) は,がんに関与する新しい細胞死経路である.
TRPM4は,NECSOと結びついている唯一のタンパク質で,ボルテゾミブ耐性多発性骨髄腫 (MM) でダウンレギュレーションされています.

研究の目的:

シノブファギンのボルテゾミブ耐性を克服する可能性を調査する.
TRPM4とNECSO誘導に焦点を当てたシノブファギンのメカニズムを解明する.

主な方法:

in vitro MM細胞系と in vivo 異種移植モデルを使用した.
腫瘍増殖,TRPM4発現,NECSO誘導に対するシノブファギンの影響を評価した.
先進的な分子技術を用いて,SEC62/TRPM4の相互作用,ユビキチン化,および分解経路を調査した.

主要な成果:

シノブファギンは,ボルテゾミブ耐性MM細胞の増殖と腫瘍の増殖を抑制した.
シノブファギンはTRPM4を上昇させ,NECSOを誘導し,SEC62-TRPM4の相互作用を妨げました.
SEC62- TRPM4の破壊は,そのタンパク質分解を防止し,ボルテゾミブ耐性を逆転させ TRPM4を安定させました.

結論:

TRPM4はボルテゾミブ耐性MMの有効な治療標的である.
シノブファギンは,SEC62-TRPM4軸を調節し,NECSOを誘導することで抵抗を克服します.
シノブファギンは,耐性多発性骨髄腫の治療において有意な治療の可能性を示しています.

キーワード:

ボロン耐性多発性骨髄腫シノブファギン NECSO SEC62 についてターゲット識別

さらに関連する動画

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

関連する概念動画

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...